Policy & Regulation
Neuvogen appoints new director
26 February 2021 -

Neuvogen, an immunoncology company, has named Alan C Mendelson as its new director it was reported on Thursday.

Mendelson served as a partner at Latham & Watkins LLP, where he held several leadership roles. Prior to Latham & Watkins he was a partner at Cooley LLP. He has served as acting general counsel of Cadence Design Systems Inc. He has held the position of secretary and acting general counsel of Amgen Inc. He earlier served on the boards of directors of several public biotech companies including Aviron Inc, CV Therapeutics Inc, QLT Inc, and Valentis Inc. He has also held the position of corporate secretary for Mellanox Technologies Ltd, Intuitive Surgical Inc, Corvus Pharmaceuticals Inc, Eargo Inc and 4D Molecular Therapeutics Inc. Presently, he serves on the board of directors of Coherus Biosciences, the California Life Sciences Association and the boards of trustees of the University of California, Berkeley Foundation and The Buck Institute for Research on Aging.

Mendelson, said, 'I am thrilled to be joining the NEUVOGEN board of directors at this stage in the company's growth and progress. I welcome the opportunity to continue to work with such a talented business and scientific team. I am particularly interested in the company's systems approach to solving solid tumours and the remarkable opportunity that creates for substantial patient benefit and sizeable market value.'



Related Headlines